A5053353310- SARS-CoV-2 detection and testing
- SARS-CoV-2 and COVID-19 Research
- Respiratory viral infections research
- COVID-19 diagnosis using AI
- Biosensors and Analytical Detection
- Advanced biosensing and bioanalysis techniques
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cardiac, Anesthesia and Surgical Outcomes
- Lung Cancer Treatments and Mutations
- Delphi Technique in Research
- Medical Malpractice and Liability Issues
University of Calgary
2020-2022
Alberta Health Services
2020
Introduction. The ID NOW is FDA approved for the detection of SARS-CoV-2 in symptomatic individuals within first 7 days symptom onset COVID-19 if tested 1 h specimen collection. Gap statement. Clinical data on performance are limited, with many studies varying their study design and/or having small sample size. Aim. In this we aimed to determine clinical compared conventional RT-PCR testing. Methodology. Adults community or hospital were recruited into study. Paired throat swabs collected,...
Point-of-care SARS-CoV-2 antigen tests have great potential to help combat the COVID-19 pandemic. In performance of a rapid, antigen-based test (RAT), our study had 3 main objectives: determine accuracy nasal swabs, using nasopharyngeal swabs for collection (nasalNP), and effectiveness residual extraction buffer real-time reverse-transcriptase PCR (RT-PCR) confirmation positive RAT (rPan).
Abstract Background As surgical systems are forced to adapt and respond new challenges, so should the patient safety tools within those systems. We sought determine how WHO SSC might best be adapted during COVID‐19 pandemic. Methods 18 Panelists from five continents multiple clinical specialties participated in a three‐round modified Delphi technique identify potential recommendations, assess agreement with proposed recommendations address items not meeting consensus. Results From an initial...
INTRODUCTION Point of care diagnostic tests for SARS-CoV-2, such as the ID NOW, have great potential to help combat COVID-19 pandemic. The NOW is approved by United States Food and Drug Administration (FDA) detection SARS-CoV-2 in symptomatic individuals within first 7 days symptom onset if tested 1 hour specimen collection. However, clinical data on performance limited, with many studies deviating from manufacturer’s instructions and/or having small sample size. METHODS Adults community or...
ABSTRACT BACKGROUND Point of Care Testing (POCT) SARS-CoV-2 antigen tests, such as the Abbott Panbio, have great potential to help combat COVID-19 pandemic. The Panbio is Health Canada approved for detection in symptomatic individuals within first 7 days symptom onset(s). METHODS Symptomatic adults recently diagnosed with community were recruited into study. Paired nasopharyngeal (NP), throat, and saliva swabs collected, one paired swab tested immediately other transported universal...
Abstract BACKGROUND Point of Care SARS-CoV-2 antigen tests, such as the Abbott Panbio, have great potential to help combat COVID-19 pandemic. The Panbio is Health Canada approved for detection in symptomatic individuals within first 7 days symptom onset(s). METHODS Symptomatic adults recently diagnosed with community were recruited into study. Paired nasopharyngeal (NP), throat, and saliva swabs collected, one paired swab tested immediately other transported universal transport media using...